Dr. Robin L. Jones on Eribulin Versus Dacarbazine in Patients With Leiomyosarcoma and Adipocytic Sarcoma
Robin L. Jones, BSc, MB, MRCP, MD, Consultant Oncologist, Royal Marsden Hospital, London, England, discusses results and takeaways from a phase III trial presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
Robin L. Jones, BSc, MB, MRCP, MD, Consultant Oncologist, Royal Marsden Hospital, London, England, discusses results and takeaways from a phase III trial presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
This randomized phase III trial analyzed patients with unresectable metastatic liposarcoma or leiomyosarcoma who had previously received at least two lines of chemotherapy. The primary endpoint was overall survival (OS).
In the trial, eribulin demonstrated significant benefit for patients: OS was 13.5 months compared with 11.5 months with dacarbazine.
Jones points out that this trial is significant because OS benefit is seldom seen soft tissue sarcoma studies.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
